[go: up one dir, main page]

WO2009029762A3 - Farnesylamine inhibitors of the visual cycle - Google Patents

Farnesylamine inhibitors of the visual cycle Download PDF

Info

Publication number
WO2009029762A3
WO2009029762A3 PCT/US2008/074743 US2008074743W WO2009029762A3 WO 2009029762 A3 WO2009029762 A3 WO 2009029762A3 US 2008074743 W US2008074743 W US 2008074743W WO 2009029762 A3 WO2009029762 A3 WO 2009029762A3
Authority
WO
WIPO (PCT)
Prior art keywords
visual cycle
farnesylamine
inhibitors
drug
visual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/074743
Other languages
French (fr)
Other versions
WO2009029762A2 (en
Inventor
Robert R Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2009029762A2 publication Critical patent/WO2009029762A2/en
Publication of WO2009029762A3 publication Critical patent/WO2009029762A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits or antagonizes the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
PCT/US2008/074743 2007-08-31 2008-08-29 Farnesylamine inhibitors of the visual cycle Ceased WO2009029762A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96928907P 2007-08-31 2007-08-31
US60/969,289 2007-08-31

Publications (2)

Publication Number Publication Date
WO2009029762A2 WO2009029762A2 (en) 2009-03-05
WO2009029762A3 true WO2009029762A3 (en) 2009-04-23

Family

ID=40388126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/074743 Ceased WO2009029762A2 (en) 2007-08-31 2008-08-29 Farnesylamine inhibitors of the visual cycle

Country Status (1)

Country Link
WO (1) WO2009029762A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US20060069078A1 (en) * 2004-02-17 2006-03-30 Rando Robert R Management of ophthalmologic disorders, including macular degeneration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510510A (en) * 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US20060069078A1 (en) * 2004-02-17 2006-03-30 Rando Robert R Management of ophthalmologic disorders, including macular degeneration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLCZAK M. ET AL.: "Positively charged retinoids are potent and selective inhibitors of the trans- cis isomerization in the retinoid (visual) cycle.", PROC NATL ACAD SCI U S A., vol. 102, no. 23, 7 June 2005 (2005-06-07), pages 8162 - 7, XP008107477, DOI: doi:10.1073/pnas.0503318102 *
GOLLAPALLI DR ET AL.: "The specific binding of retinoic acid to RPE65 and approaches to the treatment of macular degeneration.", PROC NATL ACAD SCI U S A., vol. 101, no. 27, 6 July 2004 (2004-07-06), pages 10030 - 5, XP003023101, DOI: doi:10.1073/pnas.0401936101 *
MAEDA A ET AL.: "Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice.", MOL PHARMACOL., vol. 4, October 2006 (2006-10-01), pages 1220 - 9, XP002680489, DOI: doi:10.1124/MOL.106.026823 *

Also Published As

Publication number Publication date
WO2009029762A2 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
WO2005079774A3 (en) Management of ophthalmologic disorders, including macular degeneration
WO2007019503A3 (en) Management of ophthalmologic disorders, including macular degeneration
PH12017500930A1 (en) Hsp90 inhibitor combinations
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
WO2009129486A3 (en) Timing therapy evaluation trials
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2007146426A3 (en) Nanoshells for drug delivery
HK1223319A1 (en) Methods for treating or preventing ophthalmological conditions
PL2364983T3 (en) Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
ZA201005905B (en) Methods,dosage forms,and kits for administering ziprasidone without food
WO2009142731A3 (en) Niacin and nsaid for combination therapy
BR112012003462A2 (en) "compound, pharmaceutical composition, and method for treating a patient having a protein kinase mediated condition."
BRPI0916102A2 (en) "Method for the prevention of paraestomal hernia, method for preparing a paraestomal hernia and device for preparing or reducing the incidence of paraestomal hernia"
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
BR112012003280A2 (en) pharmaceutical composition for oral administration, method for treating a disease, use of the compound, and, compound.
WO2011108826A3 (en) Complex formulation for oral administration comprising probiotic formulation and 5-ht4 receptor agonist and method for the preparation thereof
WO2009149056A3 (en) Combinations of niacin and an oxicam
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EP2012807A4 (en) Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
WO2009144551A3 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium level in the blood
WO2009149058A8 (en) Modified release niacin formulations
WO2008093247A3 (en) Medicament for the treatment of endometriosis
BRPI0914323A2 (en) compound, pharmaceutical formulation, use of a compound, and methods for treating a condition and treating and preventing disorders
WO2010120817A3 (en) Nanochanneled device and related methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08798936

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08798936

Country of ref document: EP

Kind code of ref document: A2